Ind-Swift Labs Receives GMP Certificate from Hungary, Opens European Markets
Ind-Swift Laboratories received a GMP certificate from Hungary following a November 2025 inspection. The certificate is valid for three years and opens European markets. The company also holds WHO-GMP, TGA, MHRA, SAPRA, and EU-GMP certifications.
The receipt of a GMP certificate from a European regulatory body like Hungary is a positive development that can lead to expanded market access and potentially increased revenue, thus impacting the company's business operations.
The company has received a significant GMP certification from Hungary, which is expected to open up new markets. This is a positive development for the company's business prospects.
Ind-Swift Laboratories Limited's Global Business Unit (Formulations Facility) located in Derabassi, Punjab, has received a Good Manufacturing Practice (GMP) compliance certificate from the National Center for Public Health and Pharmacy (NNGYK) in Hungary. This certification follows a successful EUDRA GMP inspection conducted in November 2025 and is valid for three years. The GMP certificate is expected to open up European and other international markets for the company's products.
This new certification from Hungary complements the existing certifications held by Ind-Swift Laboratories' global business unit, which include WHO-GMP, TGA (Australia), MHRA (UK), SAPRA (South Africa), and EU-GMP. The company views this achievement as a reinforcement of its commitment to upholding the highest standards of quality, safety, and regulatory compliance in its operations, demonstrating dedication to meeting stringent global regulatory requirements.
What to do with a filing like this
Ind-Swift Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under other company updates. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ind-Swift Laboratories Limited. Read the original for the full detail.